Locations:

Uncontrolled Seizures: Their Sobering Implications and the Case for Surgical Interventions (Podcast)

Exploring when and how to consider epilepsy surgery or neuromodulation

Recent data from the Centers for Disease Control and Prevention show that more than half of U.S. adults who take epilepsy medications still have seizures. This fact has made Cleveland Clinic Epilepsy Center Director Imad Najm, MD, a vocal advocate of the guideline recommendation that patients consider other treatment options — including epilepsy surgery and neuromodulation — when two or more anti-epileptic medications fail to prevent their seizures.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In the newest episode of Cleveland Clinic’s peer-to-peer Neuro Pathways podcast, Dr. Najm discusses what we now know about pharmacoresistant epilepsy and the latest advances in identifying candidates for epilepsy surgery or neuromodulation therapies. Among the topics explored:

  • Implications of medically intractable and uncontrolled seizures
  • Identifying the best candidates for epilepsy surgery
  • The comparative profiles of three available neuromodulation therapies for refractory epilepsy
  • Why surgical outcomes are so varied
  • How technologies for epilepsy presurgical evaluation have become less invasive and more revealing over the past decade

Click the player above to listen to the 20-minute podcast now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Excerpt from the podcast

Dr. Najm: The number of epilepsy surgeries done in the United States is close to 3,000 per year. It is estimated that around 150,000 patients are surgical candidates in the United States alone. Plus, it’s estimated that we have another 15,000 patients per year who will become surgical candidates in addition to the 150,000. This data is sobering because it tells us that even in a country like the United States, where we have access to high-level medical resources, epilepsy surgery is not used to the extent it should be.

It is very important to know that seizures can lead to disability, fractures, head injuries, bodily injuries and skin injuries. In addition, seizures that are not controlled — even one seizure every five years — can lead to a significant increase in sudden unexpected death in epilepsy (SUDEP). The risk of SUDEP increases up to 15 times in patients who have recurrent seizures, in particular those who suffer from generalized convulsive seizures.

Advertisement

Data clearly show that the only way we can eliminate the risk of SUDEP is through complete control of seizures, not partial control. That’s why when we are asked, “What is your goal in treating patients with epilepsy?” the answer is very simple: zero seizures. It’s not like, “Oh, this patient has one seizure per month during the nighttime. It’s not disabling them.” It may not be disabling them, but it’s putting their life at risk.

Advertisement

Related Articles

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650×450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

illustration of a bright clinical room with clinicians inside

Inside Our Neurological Institute’s Next-Generation Advanced Therapeutics Space

Combining customized care, research capabilities and flexibility for the future

stylized illustration of human brain made up of cogs and wheels
October 9, 2026/Neurosciences/Brain Health

How Alzheimer’s Disease Studies Need to Evolve in the Targeted Therapy Era

Leading investigators outline a new roadmap for clinical trials and observational research

Older man tending to houseplants

TEMPO-2 Trial Shows Promise for Tavapadon in Newly Diagnosed Parkinson’s Disease

The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.

illustration of human brain with swirls of activity inside it
September 23, 2026/Neurosciences/Brain Health

Cleveland ADRC Renewal Boosts Research Into Alzheimer’s Progression

5-year funding award supports cohort expansion and deep phenotyping of AD and related dementias

young man meditating on a sofa
September 21, 2026/Neurosciences/Epilepsy

Lifestyle Interventions Show Promise as Adjunctive Epilepsy Management

Highest response rates seen with stress-lowering techniques like yoga, meditation and mindfulness

Ad